LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Sold by Congress Asset Management Co.

Congress Asset Management Co. trimmed its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 10.8% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 644,415 shares of the medical instruments supplier's stock after selling 77,910 shares during the quarter. Congress Asset Management Co. owned about 2.86% of LeMaitre Vascular worth $54,066,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of LMAT. Allspring Global Investments Holdings LLC increased its holdings in shares of LeMaitre Vascular by 48.2% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 13,321 shares of the medical instruments supplier's stock valued at $1,227,000 after purchasing an additional 4,330 shares during the last quarter. Invesco Ltd. lifted its position in shares of LeMaitre Vascular by 50.5% during the 4th quarter. Invesco Ltd. now owns 174,998 shares of the medical instruments supplier's stock worth $16,124,000 after buying an additional 58,720 shares during the last quarter. Barclays PLC lifted its position in LeMaitre Vascular by 394.5% during the 3rd quarter. Barclays PLC now owns 36,577 shares of the medical instruments supplier's stock worth $3,396,000 after acquiring an additional 29,180 shares during the period. Compass Planning Associates Inc purchased a new position in shares of LeMaitre Vascular during the 4th quarter worth approximately $567,000. Finally, Teacher Retirement System of Texas increased its position in LeMaitre Vascular by 31.8% during the 4th quarter. Teacher Retirement System of Texas now owns 101,851 shares of the medical instruments supplier's stock worth $9,385,000 after purchasing an additional 24,586 shares in the last quarter. Institutional investors own 84.64% of the company's stock.

LeMaitre Vascular Stock Up 0.4%

NASDAQ:LMAT traded up $0.31 during midday trading on Tuesday, hitting $83.63. The company had a trading volume of 110,343 shares, compared to its average volume of 168,380. The company has a market capitalization of $1.89 billion, a PE ratio of 45.70, a P/E/G ratio of 2.22 and a beta of 0.83. The stock's fifty day moving average price is $83.68 and its 200-day moving average price is $90.69. LeMaitre Vascular, Inc. has a 52-week low of $71.42 and a 52-week high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.02). LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The company had revenue of $59.87 million during the quarter, compared to the consensus estimate of $57.61 million. During the same period last year, the firm posted $0.44 earnings per share. The company's revenue was up 12.0% compared to the same quarter last year. As a group, research analysts forecast that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, May 29th. Investors of record on Thursday, May 15th were issued a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a yield of 0.96%. The ex-dividend date of this dividend was Thursday, May 15th. LeMaitre Vascular's payout ratio is currently 40.40%.

Analyst Ratings Changes

Several brokerages have issued reports on LMAT. Barrington Research downgraded shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Oppenheimer cut LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th. Wells Fargo & Company began coverage on shares of LeMaitre Vascular in a research report on Thursday, February 13th. They set an "equal weight" rating and a $95.00 target price on the stock. Finally, Lake Street Capital upped their price objective on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the stock a "buy" rating in a research note on Friday, February 28th. Five equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $97.83.

Insider Activity

In related news, CEO George W. Lemaitre sold 4,399 shares of LeMaitre Vascular stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $85.10, for a total value of $374,354.90. Following the completion of the transaction, the chief executive officer now owns 1,827,003 shares in the company, valued at approximately $155,477,955.30. The trade was a 0.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Trent G. Kamke sold 2,009 shares of the company's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total value of $164,979.08. Following the completion of the transaction, the insider now directly owns 5,564 shares of the company's stock, valued at $456,915.68. This trade represents a 26.53% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 102,009 shares of company stock worth $8,721,836. Company insiders own 9.50% of the company's stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.